The story of the erectile dysfunction drug presents a challenging picture for shareholders. While the initial launch generated massive returns, the lapse of its exclusive rights opened the door to generic alternatives, https://bookmarkswing.com/story23400360/the-copyright-and-big-pharma-a-precarious-opportunity